Tonix Pharmaceuticals has a diverse pipeline of drugs in various stages of development. Here are some of the key candidates:
TNX-102 SL: This is their lead candidate for fibromyalgia, with two positive Phase 3 studies completed. They plan to file a New Drug Application (NDA) in the second half of 2024. It’s also being developed for acute stress disorder and fibromyalgia-type Long COVID1.
TNX-1300: Currently in mid-Phase 2, this drug is for treating cocaine intoxication and has received Breakthrough Therapy Designation1.
TNX-1500: This is in Phase 1 for preventing organ transplant rejection and treating autoimmune disorders1.
TNX-1700: In preclinical development for gastric and colorectal cancer1.
TNX-801: A vaccine candidate for smallpox and monkeypox, currently in preclinical stages1.
TNX-1800: A COVID-19 vaccine candidate, also in preclinical development1.
TNX-2900: This drug is in Phase 2 for Prader-Willi Syndrome and has received FDA Orphan Drug and Rare Pediatric Disease Designation1.
Tonix is also working on other programs targeting central nervous system disorders, immunology conditions, infectious diseases, and rare diseases1.
No comments:
Post a Comment